Back to Research Hub
Ascendis Pharma A/S
ASND
$213.23+7.42 (+3.61%)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD).
StreetsValue research for Ascendis Pharma A/S (ASND)
Members get the full report for Ascendis Pharma A/S: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.